A retrospective review of pregnancies on biologics for the treatment of dermatological conditions.

Publisher: Oxford University Press Country of Publication: England NLM ID: 7606847 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2230 (Electronic) Linking ISSN: 03076938 NLM ISO Abbreviation: Clin Exp Dermatol Subsets: MEDLINE

Publication: 2023- : Oxford : Oxford University Press
Original Publication: Oxford : Blackwell Scientific Publications.

Antibodies, Monoclonal/*adverse effects ; Biological Factors/*therapeutic use ; Pregnancy/*drug effects ; Psoriasis/*drug therapy ; Skin Diseases/*drug therapy; Adult ; Antibodies, Monoclonal/therapeutic use ; Biological Factors/adverse effects ; Contraception/standards ; Female ; Humans ; Immunosuppression Therapy/adverse effects ; Infant, Newborn ; Maternal-Fetal Exchange/immunology ; Pregnancy Complications/chemically induced ; Pregnancy Complications/epidemiology ; Pregnancy Outcome ; Pregnancy Trimester, Third ; Retrospective Studies ; Safety ; Young Adult

Psoriasis often first presents in young adulthood, with the average age of diagnosis in women being 28 years, thus in the prime reproductive years. In addition, approximately 50% of pregnancies worldwide are unplanned. Although biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis, there are no controlled studies of biologics in pregnant women. The increasing use of these agents in women of childbearing age highlights the need to further assess their safety during pregnancy. Postmarketing experience regarding the safety of these drugs is accumulating and being published, with largely reassuring results. We present our real-world experience of 17 pregnancies occurring in women on treatment with biologic agents for dermatological conditions to further add to the body of knowledge.
(© 2020 British Association of Dermatologists.)

Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al. BAD guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 628-36.
Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-33.
Malek A, Sager R, Kuhn P et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36: 248-55.
Cheent K, Nolan J, Shariq S et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohns Colitis 2010; 4: 603-5.
Pottinger E, Woolf RT, Exton LS et al. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol 2018; 178: 95-10.
Mariette X, Förger F, Abraham B et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77: 228-33.
Lebwohl M, Blauvelt A, Paul C et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blinded, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol 2018; 79: 266-76. e5.
Gottlieb AB, Blauvelt A, Thaçi D et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79: 302-14.e6.
Glover L, Fennimore B, Wingfield M. Inflammatory bowel disease: influence and implications in reproduction. Inflamm Bowel Dis 2016; 22: 2724-32.
Jawaheer D, Zhu J, Nohr E et al. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum 2011; 63: 1517-21.

0 (Antibodies, Monoclonal)
0 (Biological Factors)

Date Created: 20200503 Date Completed: 20210902 Latest Revision: 20211204

20231215

10.1111/ced.14263

32359186